Harold Keer
Corporate Officer/Principal presso Stanford University
Profilo
Harold Keer is a Clinical Faculty Member at Stanford University.
He previously worked as a Principal at Titan Pharmaceuticals, Inc., Vice President-Clinical Development at Exelixis, Inc., and Vice President-Clinical Development at Five Prime Therapeutics, Inc. Keer earned a doctorate degree from Northwestern University.
Posizioni attive di Harold Keer
| Società | Posizione | Inizio |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
Precedenti posizioni note di Harold Keer
| Società | Posizione | Fine |
|---|---|---|
| EXELIXIS, INC. | Direttore Tecnico/Scientifico/R&S | - |
| TITAN PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| FIVE PRIME THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Harold Keer
| Northwestern University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| EXELIXIS, INC. | Health Technology |
| TITAN PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
- Borsa valori
- Insiders
- Harold Keer